Andrew Slimmon, Morgan Stanley Investment Management senior portfolio manager, joins 'Squawk Box' to discuss the latest ...
In a report released today, Betsy Graseck from Morgan Stanley maintained a Buy rating on Goldman Sachs Group (GS – Research Report), with a ...
Morgan Stanley says it's bullish on medtech in 2025 and upgraded Intuitive Surgical (ISRG), Tandem (TNDM), Stryker (SYK), ...
Perhaps better late than never, Morgan Stanley has jumped on board the U.S. train — moving its rating on U.S. stocks to overweight, and targeting 6,500 at the end of 2025, compared to a June ...
The stock market remains volatile. After opening in the green on December 10th, the market declined. Meanwhile, a global ...
The S&P 500 has delivered a median return of +1.5% during this month over the past 45 years, with positive results occurring ...
Morgan Stanley analyst Ryan Kenny upgraded Moelis (MC) to Overweight from Underweight with a price target of $92, up from $66. After this ...
In this piece, we will take a look at Morgan Stanley’s top cyclical stocks for an economic recovery. As 2024 approaches its end, the stock market has been through it all. The driving theme of ...
It’s extremely difficult to predict short-term moves in the market with any accuracy. But the research, analysis, and ...
Investing.com - Morgan Stanley (NYSE:MS) has revised its stance on the solar energy space, downgrading three stocks from Equal Weight to Underweight. The downgrades, targeting SolarEdge (NASDAQ ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $123.62, a high estimate of $142 ...